Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Apple

Amgen

Cisco Systems

Kinder Morgan

Merck

Microsoft

UnitedHealth Group

Verizon

Walgreens

The Dow is an excellent starting place if you are looking for foundational holdings. However, some Dow stocks would be best for investors to avoid right now.

There Are Only 5 Dow Stocks I Wouldn't Buy in 2024

Chevron

Coca-Cola

Whether you are a beginner or a professional investor, a small amount can go a long way. Investing in dividend stocks can not only help build a strong portfolio, but also generate steady passive income for you.

Disaster-Proof Dividends: 3 Stocks with Resilient Payouts in Tough Times

In the most recent trading session, Johnson & Johnson (JNJ) closed at $156.58, indicating a +0.15% shift from the previous trading day.

Johnson & Johnson (JNJ) Laps the Stock Market: Here's Why

Abbott Labs

Amazon

Donaldson

Danaher

Disney

Goldman Sachs

PepsiCo

Valmont Industries

This year's list is a bit more defensive than in years past and has a focus on earnings growth.

Investor Michael Farr is back with his top 10 stocks he's buying for 2024, and the tilt is defensive

American States Water

Cincinnati Financial

Colgate-Palmolive

Dover

Emerson Electric

Genuine Parts

Hormel Foods

Lancaster Colony

Nordson

Northwest Natural Gas

Procter & Gamble

Parker-Hannifin

Dividend Kings are the crème de la crème of dividend growers, and should be top of mind for any investor who puts income stability above all else.

15 Dividend Kings for Decades of Dividend Growth

Mobilicom 

Vanguard Intermediate-Term Corporate Bond ETF

Although next year looks to be a good time to invest in risk assets like Bitcoin ( BTC-USD ), investors with a lower risk tolerance look toward safe havens to grow their income. Some of these haven assets provide diversification benefits for investors who engage in risky positions elsewhere.

Safe Havens: 3 Fixed-Income Securities for a Balanced Portfolio in 2024

Warren Buffett's investing company, Berkshire Hathaway, let go of two stocks that have more than 60 years of consecutive annual dividend raises under their belts. Berkshire Hathaway closed its Johnson & Johnson position, possibly in response to the healthcare conglomerate's recent spinoff.

Warren Buffett Dumped These 2 Top Dividend Stocks. Should You Follow His Lead?

Biogen

Pfizer

The United States leads globally in the healthcare sector, with its innovative healthcare stocks drawing attention from an impressive $4.3 trillion in spending. As the American Medical Association highlights, this expenditure equals nearly $13,000 per person, contributing 18.3% to the nation's GDP.

Healthcare Heroes: 3 Stocks Innovating in Medicine and Wellness

Walgreens, Chevron, and Johnson & Johnson are the three worst performers on the Dow Jones Industrial Average in 2023. All three have clear reasons for their underperformance.

Is It Time to Buy the Dow Jones' 3 Worst Performing Stocks This Year?

Dow Inc

It's time for followers of the Dogs of the Dow stock-picking strategy to rebalance their portfolios.

What Are the Dogs of the Dow for 2024?

Bristol-Myers

Estee Lauder

Moderna

NextEra Energy

Exxon Mobil

Investors scored big-time on the biggest S&P 500 stocks this year. But those who picked the wrong stocks suffered mightily.

Investors Lose $426 Billion On These 8 Giant Losers This Year

Realty Income Corp

Waste Management

While the upcoming new year generally brings optimistic sentiment to the market, investors should be prepared for anything, which is why solid dividend stocks represent an incredibly relevant topic. Much like playing the hot corner, you've got to be ready for anything.

7 Rock-Solid Dividend Stocks to Trust in Difficult Times

Sponsored: Tips for Investing A financial advisor can help you understand the advantages and disadvantages of investment properties.

6 Reasons to Avoid Johnson & Johnson (JNJ) At All Costs

Vertex Pharmaceuticals

Your year-end bonus looks great now. But it may look even better in a few years if you invest it in some top-quality stocks.

5 Top Stocks to Buy With Your End-of-the-Year Bonus

Johnson & Johnson is entering the surgical robotics market with the Ottava surgical system, potentially gaining a strong market position. Ottava's design offers competitive advantages over the dominant da Vinci system, including a smaller footprint and potential cost savings for healthcare organizations. The global surgical robotics market is expected to grow rapidly providing a significant growth opportunity for JNJ, which is well-positioned with its established capabilities and brand reputation.

Johnson & Johnson: Ottava Surgical Robot Is A Growth Tailwind

McDonald's

You heard it here: 2024 could be an excellent year for stocks. The economy is improving, and specifically the third-quarter results were better than expected.

Build Your Future Portfolio: 3 Generous Dividend Stocks

First Solar

Soon, it will be that favorite time of the quadrennial cycle where American citizens will decide the future of this great nation, subsequently necessitating a discussion about election year stocks. On surface level, you might think that such periods would be rather disastrous for equities, especially with the vituperative environment.

7 Stocks That Might Win on Election Year Uncertainty

News for Johnson & Johnson Stock (JNJ)